(CercleFinance.com) – Ipsen presents at ASCO GI the phase III NAPOLI 3 trial on the Onivyde® regimen, which has shown positive results in terms of survival in previously untreated metastatic pancreatic ductal adenocarcinoma.
The investigational Onivyde® (irinotecan liposome injection) treatment in the NALIRIFOX treatment regimen demonstrated statistically significant improvements in overall survival and progression-free survival compared to nab-paclitaxel plus gemcitabine with a manageable safety profile.
“These results represent a potential breakthrough in an aggressive and difficult to treat cancer,” the group said.